Area of research
Cancer Research · Oncology
Research interest
Research interests include Breast Cancer Treatment Studies, HER2/EGFR in Cancer Research, Cancer Immunotherapy and Biomarkers, and Cancer Genomics and Diagnostics.
Longitudinal profiling identifies co-occurring BRCA1/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor-resistant advanced breast cancer
Image‐based multiplex immune profiling of cancer tissues: translational implications. A report of the International Immuno‐oncology Biomarker Working Group on Breast Cancer
Pitfalls in machine learning‐based assessment of tumor‐infiltrating lymphocytes in breast cancer: A report of the International Immuno‐Oncology Biomarker Working Group on Breast Cancer
Spatial analyses of immune cell infiltration in cancer: current methods and future directions: A report of the International Immuno‐Oncology Biomarker Working Group on Breast Cancer
Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial
Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer
Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial
Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor–Positive Early Breast Cancer: PALLET Trial
PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer
Defining Breast Cancer Intrinsic Subtypes by Quantitative Receptor Expression
Abstract S3-01: The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or <i>BRCA1/2</i> breast cancer (CRUK/07/012)
Genomic Complexity Profiling Reveals That HORMAD1 Overexpression Contributes to Homologous Recombination Deficiency in Triple-Negative Breast Cancers
NEOCENT: a randomised feasibility and translational study comparing neoadjuvant endocrine therapy with chemotherapy in ER-rich postmenopausal primary breast cancer
Molecular Characterization of Basal-Like and Non-Basal-Like Triple-Negative Breast Cancer
Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen